Relief Therapeutics Announces Results of Annual General Meeting

Rhea-AI Summary

Relief Therapeutics (RLFTY) held its Annual General Meeting on June 12, 2025, where shareholders approved all proposed resolutions with over 85% support. Key approvals included the 2024 annual report and financial statements, carrying forward the 2024 financial year net result, and granting discharge to the board and executive committee. The meeting re-elected Dr. Raghuram Selvaraju as chairman, along with board members Gregory Van Beek, Peter de Svastich, and Thomas Elzinga. Shareholders approved compensation packages for the board and executive committee, the 2024 compensation report, and re-appointed Thomas Hua as independent proxy and FORVIS MAZARS SA as statutory auditor.

Shareholders approved all proposals by a large majority

GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the results of its annual general meeting (AGM) of shareholders, held earlier today in Geneva. All proposed resolutions were approved by more than 85 percent of the represented votes.

AGM Results

1. Annual Report and Financial Statements for the Year 2024

The AGM approved the 2024 annual report and financial statements.

2. Appropriation of Available Earnings

The AGM approved carrying forward the net result for the 2024 financial year.

3. Discharge of the Board of Directors and the Executive Committee

The AGM granted discharge to the board of directors and the executive committee for the 2024 financial year.

4. Elections to the Board of Directors

The AGM re-elected Dr. Raghuram Selvaraju, Mr. Gregory Van Beek, Mr. Peter de Svastich, and Mr. Thomas Elzinga to the board of directors. Dr. Selvaraju was re-elected as chairman of the board. Mr. de Svastich and Dr. Selvaraju were re-elected as members of the nomination and compensation committee.

5. Compensation of the members of the Board of Directors and of the Executive Committee

The AGM approved the proposed maximum compensation amounts for the board of directors for the period from AGM 2025 to AGM 2026, and for the executive committee for the 2026 financial year. Shareholders also approved, on a consultative basis, the 2024 compensation report.

6. Independent Voting Rights Representative

The AGM re-elected Mr. Thomas Hua as the Company's independent proxy.

7. Auditors

The AGM re-elected FORVIS MAZARS SA as the Company's statutory auditor.

The full text of the resolutions submitted to shareholders is available in the AGM Invitation. The detailed voting results will be published on the Company's website later today.

ABOUT RELIEF

Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com

CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com

DISCLAIMER
This press release may contain forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holding SA

View the original press release on ACCESS Newswire

FAQ

What were the key decisions made at Relief Therapeutics (RLFTY) 2025 AGM?

At the 2025 AGM, shareholders approved the 2024 annual report, financial statements, board re-elections including Dr. Selvaraju as chairman, compensation packages, and re-appointed FORVIS MAZARS SA as auditor.

Who was re-elected to Relief Therapeutics board of directors in 2025?

Dr. Raghuram Selvaraju (as chairman), Gregory Van Beek, Peter de Svastich, and Thomas Elzinga were re-elected to the board of directors.

What percentage of shareholders approved the resolutions at Relief Therapeutics 2025 AGM?

All proposed resolutions were approved by more than 85 percent of the represented votes.

Who are the auditors for Relief Therapeutics (RLFTY)?

FORVIS MAZARS SA was re-elected as the company's statutory auditor at the 2025 AGM.